Effects of endothelin receptor antagonism relate to the degree of renin-angiotensin system blockade in chronic proteinuric kidney disease.
Dhaun
Neeraj
N
Macintyre
Iain M
IM
Melville
Vanessa
V
Lilitkarntakul
Pajaree
P
Johnston
Neil R
NR
Goddard
Jane
J
Webb
David J
DJ
D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D065128:Endothelin Receptor Antagonists; D005923:Glomerulosclerosis, Focal Segmental / Q000150:complications / Q000188:drug therapy; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000188:drug therapy*; D010456:Peptides, Cyclic / Q000627:therapeutic use*; D011507:Proteinuria / Q000150:complications / Q000188:drug therapy*; D012084:Renin-Angiotensin System / Q000187:drug effects*; D016896:Treatment Outcome
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D065128:Endothelin Receptor Antagonists; D010456:Peptides, Cyclic; C072247:cyclo(Trp-Asp-Pro-Val-Leu)